Интраоперационная флюоресцентная диагностика и фотодинамическая терапия больных немышечно-инвазивным раком мочевого пузыря
Диссертация
На этапе диагностики наряду с традиционными методами первичной и уточняющей диагностики, такими как уретроцистоскопия с биопсией, различные модификации ультразвукового исследования, компьютерной и спиральной томографии в последнее время большое значение имеет оценка уровня опухолевых маркеров (серологические и уринологические маркеры: UBC-тест, Cefra 21−1, ВТА, TPS, NMP-22, раково-эмбриональный… Читать ещё >
Список литературы
- Карякин О.Б. Химиолучевое лечение рака мочевого пузыря. Пленум Всероссийского общества урологов. Кемерово, 1995. С. 223−4. 36.
- Кудашев Б.В. Применение метода флуоресцентной диагностики для повышения радикализма трансуретральной резекции мочевого пузыря. Диссертация на соискание ученой степени кандидата медицинских наук, Москва, 2001.
- Мартов А.Г., Сысоев П. А., Гущин Б. Я. Сравнительные результаты ТУР и электровапоризации при поверхностном раке мочевого пузыря. Материалы 4-ой Всероссийской науч.-практич. конф. 2001- С. 68−9.
- Матвеев Б. П. Клиническая онкоурология. Москва, 2003. С. 260 5.
- Переверзев A.C., Петров С. Б. Опухоли мочевого пузыря. Харьков, 2002.
- Решетников A.B., Швец В. И., Пономарев Г. В. Водорастворимые тетрапиррольные фотосенсибилизаторы для фотодинамическойтерапии рака (обзор). Успехи химии порфиринов. 1999. Т. 2., Гл. 4. С. 70−114.
- Ю.Русаков И. Г., Быстров A.A. Хирургическое лечение, химио- и иммунотерапия больных поверхностным раком мочевого пузыря. Практическая онкология № 4, 2003- С. 214 24.
- В.В. Соколов, В. И. Чиссов, Е. В. Филоненко, Л. В. Телегина H.H. Булгакова. «Флуоресцентная диагностика начального центрального рака легкого», Пульмонология, 2005, № 1, стр. 107−116.
- Странадко Е.Ф., Скобелкин O.K., Ворожцов Г. Н. и соавт. Пятилетний опыт клинического применения фотодинамической терапии. Российский онкологический журнал, № 4, 1998- С. 13−8.
- З.Ульянов Р. В. Флюоресцентная цистоскопия и локальная спектроскопия у больных поверхностным раком мочевого пузыря. Диссертация на соискание ученой степени кандидата медицинских наук, Москва, 2008, 115 с.
- Чиссов В.И., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2009. Москва, 2011.
- Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011 Jun-59(6):997−1008. Epub 2011 Mar 22. Review.
- Babjuk M, Soukup V, Pesl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapTl bladder urothelial carcinoma. Urology. 2008 Apr-71(4):718−22.
- Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology. 2000 May-14(5):719−29.
- Benson RC Jr, Farrow GM, Kinsey JH et al. Detection and localization of In situ carcinoma of the bladder with hematoporphyrin derivative. Mayo Clin Proc. 1982 Sep-57(9):548−55.
- Berger АР, Steiner H, Stenzl A et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology. 2003 Feb-61(2):338−41.
- Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer. 2009 Nov 2−8:94.
- Bohle A, Jocham D, Bock PR et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003 Jan- 169(1):90−5.
- Botteman MF, Pashos CL, Hauser RS et al. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res. 2003 Sep-12(6):675−88.
- Brunner H, Hausmann F, Knuechel R. New 5-aminolevulinic acid esters-efficient protoporphyrin precursors for photodetection and photodynamic therapy. Photochem Photobiol. 2003 Nov-78(5):481−6.
- Burger M, Zaak D, Stief CG et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol. 2007 Jul-52(l): 142−7. Epub 2007 Jan 22.
- Casas A, Fukuda H, Di Venosa G, Batlle A. Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer. 2001 Jul 20−85(2):279−84.
- Chatterton K, Ray E, O’Brien TS. Fluorescence diagnosis of bladder cancer. Br JNurs. 2006 Jun 8−21- 15(11):595−7.
- Chowbina SR, Wu X, Zhang F et al. HPD: an online integrated human pathway database enabling systems biology studies. BMC Bioinformatics. 2009 Oct 8- 10 Suppl 11:5.
- Crossman HB. Improving the management of bladder cancer with fluorescence cystoscopy. J Environ Pathol Toxicol Oncol. 2007−26(2): 143−7
- Dalbagni G, Vora K, Kaag M. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol. 2009 Dec-56(6):903−10. Epub 2009 Jul 17.
- Datta SN, Allman R, Loh C et al. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. Br J Cancer. 1997−76(3):312−7.
- Datta SN, Loh CS, MacRobert AJ et al. Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell carcinoma. Br J Cancer. 1998 Oct-78(8):l 113−8.
- Denzinger S, Burger M. Photodynamic diagnostics of bladder tumors. Curr Urol Rep. 2008 Mar-9(2): 101−5.
- D’Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol. 2002 Nov-42(5):417−25. Review.
- Dindyal S, Nitkunan T, Bunce CJ. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther. 2008 Jun-5(2): 153−8. Epub 2008 Jul 7.
- Draga RO, Grimbergen MC, Kok ET et al. Photodynamic Diagnosis (5-Aminolevulinic Acid) of Transitional Cell Carcinoma After Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Intravesical Therapy. Eur Urol. 2009 Oct 6.42.EAU Guidelines, 2011.
- Ferro M, Giuberti G, Zappavigna S et al. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncol Rep. 2012 Feb-27(2):409−15. Epub 2011 Oct 31.
- Filbeck T, Pichlmeier U, Knuechel R et al. Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. Urologe A. 2003 Oct-42(10):1366−73. Epub 2003 Apr 25. German.
- French AJ, Datta SN, Allman R et al. Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cellline model. BJU Int. 2004 Jan-93(l):156−61.
- Furuse H, Ozono S. Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills. Int J Urol. 2010 Aug-17(8):698−9.
- Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002 Mar 15−62(6): 1604−8.
- Hamasaki T, Suzuki Y, Tomita Y et al. Efficacy of transurethral resection of the bladder tumor (TUR-BT) for huge bladder cancer. J Nihon Med Sch. 2010 Aug-77(4): 190−4.
- Hendrickx N, Dewaele M, Buytaert E et al. Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. Biochem Biophys Res Commun. 2005 Nov 25−337(3):928−35.
- Higuchi TT, Fox JA, Husmann DA. Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. J Urol. 2011 Nov- 186(5): 1791−5. Epub 2011 Sep 25.
- Hollingsworth JM, Zhang YS, Miller DC et al. Identifying Better Practices for Early-stage Bladder Cancer. Med Care. 2011 Dec-49(12):l 112−7.
- Inoue K, Kuno T, Fukuhara H et al. Clinical experience with transurethral resection of bladder tumor (TUR-Bt) guided by photodynamic diagnosis (PDD). Nihon Hinyokika Gakkai Zasshi. 2009 Nov- 100(7):661−70.
- Jichlinski P. Photodynamic applications in superficial bladder cancer: facts and hopes! J Environ Pathol Toxicol Oncol. 2006−25(1−2):441−51. Review.
- Jocham D, von Wietersheim J, Pfluger H et al. BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study. Aktuelle Urol. 2009 Mar-40(2):91−9.
- Joudi FN, O’Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol. 2004 Sep-14(5):271−5.
- Juarranz A, Jaen P, Sanz-Rodriguez F et al. Photodynamic therapy of cancer. Basic principles and applications. Clin Transi Oncol. 2008 Mar- 10(3): 148−54. Review.
- Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology. 2000 Feb- 55(2): 161−8.
- Kamuhabwa AA, Roskams T, D’Hallewin MA et al. Whole bladder wall photodynamic therapy of transitional cell carcinoma rat bladder tumorsusing intravesically administered hypericin. Int J Cancer. 2003 Nov 10−107(3):460−7.
- Kausch I, Doehn C, Jocham D. Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2006 Sep-6(9): 1301−11.
- Kausch I, Sommerauer M, Montorsi F et al. Photodynamic diagnosis in nonmuscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010 Apr-57(4):595−606. Epub 2009 Dec 2.
- Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma. Br J Cancer. 1975 Feb-31(2):237−44.
- Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol. 1976 Feb-l 15(2):150−1.
- Kobayashi Y, Saika T, Miyaji Y et al. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol. 2011 Jul 30.
- Kriegmair M, Zaak D, Stepp H et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol. 1999 Nov-36(5):386−92.
- Kundal VK, Pandith AA, Hamid A et al. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence. Asian Pac J Cancer Prev. 2010- 11 (5): 1279−82.
- Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. (Review). Urol Clin North Am. 1992 Aug-19(3):573−80.
- Lange N, Jichlinski P, Zellweger M et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999 Apr-80(l-2): 185−93.
- Lee LS, Thong PS, Olivo M et al. Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy-A potential bladder sparing option for high risk non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther. 2010 Dec-7(4):213−20.
- Lipinski MI., Jeromin LM. Value of the photodynamic method in the diagnosis of superficial bladder tumors. Wiad Lek. 2004−57 Suppl 1:192−5.
- Lindemann-Docter K, Knuchel-Clarke R. Histopathology of urothelial carcinomas: crucial for patient management. Urologe A. 2008 May-47(5):627−36- quiz 637.
- Lottner C, Knuechel R, Bernhardt G et al. Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum (II) conjugates. Cancer Lett. 2004 Jan 20−203(2): 171−80.
- Lund L, Erichsen R, Norgaard M et al. Survival of invasive bladder cancer patients, 1998−2009- a central and northern Denmark population-based cohort study. Clin Epidemiol. 2011−3 Suppl 1:47−51. Epub 2011 Jul.
- Lundbeck F, Mogensen P, Jeppesen N. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase. J Urol. 1983 Dec- 130(6):1087−9
- Malmstrom PU. Advances in intravesical therapy of urinary bladder cancer. Expert Rev Anticancer Ther. 2004 Dec-4(6): 1057−67. Review.
- Manyak MJ, Ogan K. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium. J Endourol. 2003 Oct-17(8):633−9.
- Mazzucchelli R., Barbisan F., Tarquini LM et al. Urothelial changes induced by therapeutic procedures for bladder cancer. A review. Anal Quant Cytol Histol. 2005 Feb-27(l):27−34.
- Merrill RM, Sloan A, Anderson AE, Ryker K. Unstaged cancer in the United States: a population-based study. BMC Cancer. 2011 Sep 21 -11:402.
- Morrow DI, Garland MJ, McCarron PA et al. Innovative drug delivery strategies for topical photodynamic therapy using porphyrin precursors. J Environ Pathol Toxicol Oncol. 2007−26(2):105−16.
- Mowatt G, N’Dow J, Vale L et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care. 2011 Jan-27(l):3−10.
- Nowis D, Makowski M, Stoklosa T et al. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol. 2005−52(2):339−52.
- Nseyo UO, DeHaven J, Dougherty TJ et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg. 1998 Feb-16(l):61−8.
- Palumbo G. Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin Drug Deliv. 2007 Mar-4(2):131−48. Fried NM. Therapeutic applications of lasers in urology: an update. Expert Rev Med Devices. 2006 Jan-3(l):81−94.
- Pan H, Ma X, Chen J et al. PDT combined with Intravesical BCG instillation would form an autovaccine for bladder cancer? Med Hypotheses. 2009 0ct-73(4):559−60.
- Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997 Jun 15−79(12):2282−308. Review.
- Raitanen MP- FinnBladder Group. The role of BTA stat Test in follow-up of patients with bladder cancer: results from Finn Bladder studies. World J Urol. 2008 Feb-26(l):45−50. Epub 2008 Jan 8.
- Ridgway TD, Lucroy MD. Phototoxic effects of 635-nm light on canine transitional cell carcinoma cells incubated with 5-aminolevulinic acid. Am J Vet Res. 2003 Feb-64(2):131−6.
- Rischman P. Recommendation du Comite de Cancerologie de IyAssociation Francaise dyUrologie. Tumeurs urotheliales // Prog. Urol. 1998. -Vol.8(3(5)). — P. 25.
- Saczko J, Skrzypek W, Chwilkowska A et al. Photo-oxidative action in cervix carcinoma cells induced by HPD mediated photodynamic therapy. Exp Oncol. 2009 Dec-31(4): 195−9.
- Sadzuka Y, Tokutomi K, Iwasaki F et al. The phototoxicity of photofrin was enhanced by PEGylated liposome in vitro. Cancer Lett. 2006 Sep 8−241(l):42−8. Epub 2005 Nov 21.
- Salehi A, Khezri AA, Malekmakan L, Aminsharifi A. Epidemiologic status of bladder cancer in shiraz, southern iran. Asian Pac J Cancer Prev. 2011 — 12(5): 1323−7.
- Santos Cortes JA, Grahan J, Soloway MS. Photodynamic diagnosis in urology: state of the art. Arch Esp Urol. 2011 Jan-Feb-64(l): 18−31.
- Schenkman E, Lamm DL. Superficial bladder cancer therapy. Scientific World Journal. 2004 Jun 28−4 Suppl 1:387−99.
- Schmidbauer J, Remzi M, Klatte T et al. Fluorescence Cystoscopy with High-Resolution Optical Coherence Tomography Imaging as an
- Adjunct Reduces False-Positive Findings in the Diagnosis of Urothelial Carcinoma of the Bladder. Eur Urol. 2009 Aug 5 (2): 127−31.
- Shariat SF, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomark Med. 2008 Apr-2(2): 165−80.
- Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009 Jun-27(3):295−300. Epub 2009 Mar 7.
- Skyrme RJ, French AJ, Datta SN et al. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int. 2005 Jun-95(9): 1206−10.
- Smaldone MC, Gayed BA, Tomaszewski J J, Gingrich JR. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol. 2009 Jun-61(2):71−89.
- Stanislaus P, Zaak D, Stadler T et al. Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. World J Urol. 2010 Aug-28(4):407−11.
- Stavropoulos NE, Kim A, Nseyo UU et al. Hypericum perforatum L. extract novel photosensitizer against human bladder cancer cells. J Photochem Photobiol B. 2006 Jul 3−84(l):64−9.
- Strittmatter F, Buchner A, Karl A et al. Individual learning curve reduces the clinical value of urinary cytology. Clin Genitourin Cancer. 2011 Sep-9(l):22−6. Epub2011 Jul
- Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev. Anticancer Ther. 2009 Jun-9(6):807−13.
- Van der Heijden AG, Witjes JA. Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr Opin Urol. 2003 Sep-13(5):389−95.
- Waidelich R, Beyer W, Knuchel R et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology. 2003 Feb-61(2):332−7.
- Walker MC, Masstera JR, Parris CN et al. Intravesical chemotherapy in vitro studies on the relationship between dose and cytotoxicity. Urol Res. 1986- 14(3): 137−40. (33,91)
- Wientjes MG, Badalament RA, Wang RC et al. Penetration of Mitomycin C in human bladder. Cancer Res. 1993 Jul 15−53(14):3314−20.
- Wientjes MG, Dalton JT, Badalament RA et al. A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. PharmRes. 1991 Feb-8(2): 168−73.
- Wang ST, Chang CC, Yen MC et al. RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency. Gene Ther. 2010 Nov 25. Epub ahead of print.
- Washino S, Hirai M, Matsuzaki A et al. Clinical Usefulness of CEA, CA19−9, and CYFRA 21−1 as Tumor Markers for Urothelial Bladder Carcinoma. Urol Int. 2011 Oct 28. Epub ahead of print.
- Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006 May-49(5):790−7.
- Xiao Z, Hansen CB, Allen TM et al. Distribution of photosensitizers in bladder cancer spheroids: implications for intravesical instillation of photosensitizers for photodynamic therapy of bladder cancer. J Pharm Pharm Sci. 2005 Sep 28−8(3):536−43.
- Yavari N, Andersson-Engels S, Segersten U, Malmstrom PU. An overview on preclinical and clinical experiences with photodynamic therapy for bladder cancer. Can J Urol. 2011 Aug-18(4):5778−86.
- Yee DS, Ishill NM, Lowrance WT et al. Ethnic differences in bladder cancer survival. Urology. 2011 Sep-78(3):544−9. Epub 2011 Jul.
- Zaak D, Kriegmair M, Stepp H et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology. 2001 Apr- 57(4):690−4.